1887

Abstract

Summary: We have cloned and expressed the gene of in BCG to develop a recombinant vaccine against zoonotic cutaneous leishmaniasis. Two different expression systems were investigated. The first system consists of p, a promoter, which drives expression of ORF2, an open reading frame in IS900. This system allows the production of heterologous polypeptides as hybrids with the ORF2 gene product. The second expression system relies on the production of antigenic fragments as fusion proteins with the N-terminal region of β-lactamase. Both constructs resulted in the production of Gp63 in BCG. The ability of the two recombinant BCG strains to induce protective immunity against a challenge with amastigotes was evaluated after vaccination of susceptible (BALB/c), and resistant (C57BL/6) mice. Recombinant BCG producing Gp63 as a hybrid protein with the N-terminal region of the β-lactamase elicited significant protection against a challenge with in BALB/c-immunized mice.

Loading

Article metrics loading...

/content/journal/micro/10.1099/13500872-141-7-1585
1995-07-01
2021-07-29
Loading full text...

Full text loading...

/deliver/fulltext/micro/141/7/mic-141-7-1585.html?itemId=/content/journal/micro/10.1099/13500872-141-7-1585&mimeType=html&fmt=ahah

References

  1. Adler S., Gunders A.E. 1964; Immunity of Leishmania mexicana following spontaneous recovery from oriental sore.. Trans R Soc Trop Med Hyg 58:274–277
    [Google Scholar]
  2. Aldovini A., Young R.A. 1991; Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines.. Nature 351:479–482
    [Google Scholar]
  3. Ben Ismaïl R., Gradoni L, Behini S., Ben Rachid M.S. 1986; Epidemic cutaneous leishmaniasis in Tunisia. Bio-chemical characterization of parasites.. Trans R Soc Trop Med Hyg 80:669–670
    [Google Scholar]
  4. Blackwell J.M. 1989; The macrophage resistance gene Lsh/ Itj/Bcg. . Res Immunol 40:767–826
    [Google Scholar]
  5. Blackwell J.M., Roach T.I.A., Atkinson S.E., Ajioka J.W., Barton C.H., Shaw M.A. 1991; Genetic regulation of macrophage priming activation : the Lsh gene story.. Immunol Lett 30:241–248
    [Google Scholar]
  6. Bloom B.R. 1989; Vaccines for the third world.. Nature 342:115–120
    [Google Scholar]
  7. Bordier C. 1987; The promastigote surface protease of Leishmania.. Parasitol Today 3:151–153
    [Google Scholar]
  8. Button L.L., McMaster W.R. 1988; Molecular cloning of the major surface antigen of Leishmania.. J Exp Med 167:724–729
    [Google Scholar]
  9. Button L.L, Reiner N.E., McMaster W.R. 1991; Modification of gp63 genes from diverse species of Eeishmania for expression of recombinant protein at high levels in Escherichia coli. . Mol Biochem Parasitol 44:213–224
    [Google Scholar]
  10. Casadaban M.J., Cohen S.N. 1980; Analysis of gene control signals by DNA fusion and cloning in Escherichia coli. . J Mol Biol 138:179–207
    [Google Scholar]
  11. Champsi J., McMahon-Pratt D. 1988; Membrane glycoprotein M-2 protects against Eeishmania amazonensis infection.. Infect Immun 56:3272–3279
    [Google Scholar]
  12. Chang K.P., Bray R.S. (editors) 1985 Human Parasitic Diseases: the Eeishmaniasis. Amsterdam: Elsevier;
    [Google Scholar]
  13. Chaudhuri G., Chaudhuri M., Pan A., Chang K.P. 1989; Surface acid proteinase (gp63) of Eeishmania mexicana: a metallo- enzyme capable of protecting liposome-encapsulated proteins from the phagolysosomal degradation by macrophage.. J Biol Chem 264:7483–7489
    [Google Scholar]
  14. Connell N.D., Medina-Acosta E., McMaster W.R., Bloom B.R., Russell D.G. 1993; Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guerin expressing the Eeishmania surface proteinase gp63.. Proc Natl Acad Sei USA 9011473–11477
    [Google Scholar]
  15. Fortier A.H., Mock B.A., Meitzer M.S., Nacy C.A. 1987; Mycobacterium bovis BCG-induced protection against cutaneous and systemic Eeishmania major infections of mice.. Infect Immun 55:1707–1714
    [Google Scholar]
  16. Gheorghiu M., Lagrange P., Fillastre C. 1988; The stability and immunogenicity of a dispersed grown freeze derived Pasteur BCG vaccine.. J Biol Stand 16:15–26
    [Google Scholar]
  17. Greenblatt C.L. 1980; The present and the future of vaccination for cutaneous leishmaniasis . In New Developments with Human and Veterinary Vaccines pp. 259–285 Mezhari A., Hertman I., Klinger M.A., Kohn A. Edited by New York: Alan R. Liss;
    [Google Scholar]
  18. Handman E., Mitchell G.F. 1985; Immunisation with Eeishmania receptor for macrophages protects mice against cutaneous leishmaniasis.. Proc Natl Acad Sei USA 825910–5914
    [Google Scholar]
  19. Howard J.G., Liew F.Y., Hale C., Nicklin S. 1984; Prophylactic immunization against experimental leishmaniasis. II. Further characterization of the protective immunity against fatal Eeishmania tropica infection induced by irradiated promastigotes.. J Immunol 134:450–455
    [Google Scholar]
  20. Jaffe C.L., Grimaldi G., McMahon-Pratt D. 1984; The cultivation and the cloning of Eeishmania. . In Genes and Antigens of Parasites. A Laboratory Manual 2nd edn. The Proceedings of a Course Sponsored by UNDP /World Bank/WHO. Morel C. Edited by WHO: Rio de Janeiro;
    [Google Scholar]
  21. Laemmli U.K. 1970; Cleavage of structural proteins during the assembly of the head of bacteriophage T4.. Nature 227:680–685
    [Google Scholar]
  22. Lainson R., Shaw J.J. 1977; Leishmaniasis in Brazil. XII. Observations on cross-immunity in monkeys and man infected with Eeishmania mexicana mexicana, E. m. amazonensis, E. brasfliensis brasfliensis, L. b. panamensis. . Am J Trop Med Hyg 80:29–35
    [Google Scholar]
  23. Liew F.Y., Howard J.G., Hale C. 1984; Prophylactic immunization against experimental leishmaniasis. III. Protection against fatal Eeishmania tropica infection induced by irradiated promastigotes involves Lyt-l+2 cells that do not mediate cutaneous DTH.. J Immunol 134:456–461
    [Google Scholar]
  24. Liew F.Y., Hale C., Howard J.G. 1985a; Prophylactic immunization against experimental leishmaniasis. IV. Subcutaneous immunization prevents the induction of protective immunity against fatal Eeishmania major infection.. J Immunol 135:2095–2101
    [Google Scholar]
  25. Liew F.Y., Singleton A., Cillari E., Howard J.G. 1985b; Prophylactic immunization against experimental leishmaniasis. V. Mechanism of the anti-protective blocking effect induced by subcutaneous immunization against Eeishmania major infection.. J Immunol 135:2102–2107
    [Google Scholar]
  26. McMahon-Pratt D., Rodriguez D., Rodriguez J.R., Zhang Y., Manson K., Bergman C., Rivas L., Rodrigez J.F., Lohman K.L., Ruddle N.H., Esteban M. 1993; Recombinant vaccinia viruses expressing gp46/M-2 protect against Eeishmania infection.. Infect Immun 61:3351–3359
    [Google Scholar]
  27. Matsuo K., Yamaguchi R., Yamasaki A., Tasaka K., Terasaka M., Totsuka K., Kobayashi H., Yukitake H., Yamada T. 1990; Establishment of a foreign secretion system in mycobacteria.. Infect Immun 58:4049–4054
    [Google Scholar]
  28. Mayrink W.P., Williams P., Da costa C.A., Magalhaes P.A., Melo M.N., Dias M., Oliveira Lima A., Michalick M.S.M., Ferrura Carvalho E., Barros G.C., Sessa P.A., De Alencar J.T. 1985; An experimental vaccine against American dermal leishmaniasis: experience in the State of Espirito Santo, Brazil.. Ann Trop Med Parasitol 79:259–269
    [Google Scholar]
  29. Mitchell G.F., Handman E. 1983; Eeishmania tropica major in mice: vaccination against cutaneous leishmaniasis in mice of high genetic susceptibility.. Aust J Exp Biol Med Sci 61:11–25
    [Google Scholar]
  30. Moreno F., Fowler A.V., Hall M., Silhavi T.G., Zabin I., Schwartz M. 1980; A signal peptide is not sufficient to lead β- galactosidase out of the cytoplasm.. Nature 286:356–359
    [Google Scholar]
  31. Murray A., Winter N., Lagranderie M., Hill D.F., Rauzier J., Timm J., Lederc G, Moriarty K.M., Georghiu M., Gicquel B. 1992; Expression of Escherichia coli β-lactamase in Mycobacterium bovis BCG using an expression system isolated from Mycobacterium paratuberculosis which induced humoral and cellular immune responses.. Mol Microbiol 6:3331–3342
    [Google Scholar]
  32. Ranes M.G., Rauzier J., Lagranderie M.M.G., Gicquel B. 1990; Functional analysis of pAL5000, a plasmid from Mycobacterium fortuitum: Construction of a ̒Mini̓ mycobacteriumEscherichia coli shuttle vector.. J Bacteriol 172:2793–2797
    [Google Scholar]
  33. Russell D.G., Alexander J. 1988; Effective immunization against cutaneous leishmaniasis with defined membrane-antigens reconstituted into liposomes.. J Immunol 140:1274–1279
    [Google Scholar]
  34. Russell D.G., Wilhelm H. 1986; The involvement of the major surface glycoprotein (gp63) of leishmania promastigotes in at-tachment to macrophages.. J Immunol 136:2613–2620
    [Google Scholar]
  35. Sacks D.L., Suman L.L., Shrivastava S.N., Blackwell J., Neva F.A. 1987; An analysis of T cell responsiveness in indian Kala- Azar.. J Immunol 138:908–913
    [Google Scholar]
  36. Sambrook J., Fritsch E.F., Maniatis T. 1989 Molecular Cloning-, a Eaboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory;
    [Google Scholar]
  37. Scott P.E., Pearce E., Natovitz P., Sher A. 1987; Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes.. J Immunol 139:221–227
    [Google Scholar]
  38. Snapper S.B., Lugosi L., Jekkel A., Melton R.E., Kieser T., Bloom B.R., Jacobs W.R. Jr 1988; Lysogeny and transformation in mycobacteria: stable expression of foreign genes.. Proc Natl Acad Sci USA 856987–6991
    [Google Scholar]
  39. Stover C.K., de la Cruz V.F., Feurst T.R., Burlein J.E., Benson L.A., Bennett L.T., Bansal G.P., Young J.F., Lee M.H., Hatfull G.F., Snapper S.B., Barletta R.G., Jacobs W.R., Bloom B.R. 1991; New use of BCG for recombinant vaccines.. Nature 351:456–460
    [Google Scholar]
  40. Stover C.K., Bansal G.P., Hanson M.S., Burlein J.E., Palaszynski S.R., Young J.F., Koenig S., Young D.B., Sadziene A., Barbour A.G. 1993; Protective immunity elicited by recombinant Bacille Calmette-Guérin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine.. J Exp Med 178:197–209
    [Google Scholar]
  41. Timm J., Perilli M.G., Duez C., Trias J., Orefici G., Fattorini L., Amicosante G., Oratore A., Joris B., Frére J. M., Pugsley A.P., Gicquel B. 1994a; Transcription and expression analysis, using lacZ and phoA gene fusions, of Mycobacterium fortuitum β-lactamase genes cloned from a natural isolate and a high-level β-lactamase producer.. Mol Microbiol 12:491–504
    [Google Scholar]
  42. Timm J., Lim E.M., Gicquel B. 1994b; Escherichia coli- mycobacteria shuttle vectors for operon and gene fusions to lacZ : the pJEM series.. J. Bacterial 176:6749–6753
    [Google Scholar]
  43. Titus R.G., Theodos C.M., Kimsey P.B., Shankar A., Hall L, McGurn M., Povinelli L. 1992; Role of T cells in immunity to the intracellular pathogen, Eeishmania major. . In Subcellular Biochemistry pp. 99–129 Avila J.L., > Harris J.R. Edited by New York: Plenum Press;
    [Google Scholar]
  44. Webb J.R., Button L.L., McMaster W.R. 1991; Heterogeneity of the genes encoding the major surface glycoprotein of Eeishmania donovani. . Mol Biochem Parasitol 48:173–184
    [Google Scholar]
  45. WHO 1984; The leishmaniases . In Report of a WHO Expert Commitee. Technical Report Series 701
    [Google Scholar]
  46. Winter N., Lagranderie M., Rauzier J., Timm J., Ledere C., Guy B., Kieny M.P., Gheorghiu M., Gicquel B. 1991; Expression of heterologous genes in Mycobacterium bovis BCG: induction of a cellular response against HIV-1 Nef protein.. Gene 109:47–54
    [Google Scholar]
  47. Yang D.M., Fairweather N., Button L.L., McMaster W.R., Kahl L.P., Liew F.Y. 1990; Oral Salmonella typhimurium (AroA) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis.. J Immunol 145:2281–2285
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/micro/10.1099/13500872-141-7-1585
Loading
/content/journal/micro/10.1099/13500872-141-7-1585
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error